Forge Biologics Deepens Genetic Medicine CDMO Capabilities with Leadership Team Expansion Across cGMP Manufacturing, Analytical Development, and Client Development
Retrieved on:
星期三, 一月 25, 2023
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Validation, Nationwide, AAV, Novartis, Government, Keck School of Medicine of USC, Technology transfer, Biochemistry, Barkey, Gene, University, Business development, Greiner, Senior, Cell, Therapy, Epidemiology, Samsung Biologics, Ohio State University, Growth, Bioreactor, WuXi AppTec, Problem solving, Multimedia, BioMarin Pharmaceutical, Environment, Pennsylvania State University, Consultant, Fine chemical, Vaccine, Forge, Chemistry
Prior to joining Forge, Mr. McPherson helped to scale processes and complete the technology transfer from 20L to 15,000L of biologics manufacturing.
Key Points:
- Prior to joining Forge, Mr. McPherson helped to scale processes and complete the technology transfer from 20L to 15,000L of biologics manufacturing.
- Taleen Barsoumian will lead Forge’s client development strategy and new business operations across Forge’s suite of manufacturing solutions.
- Adam Davis leads the in-house analytical development and testing team supporting clients throughout product development and manufacturing.
- Dr. Davis joined Forge in 2020 after 15 years of experience in recombinant adeno-associated viral (AAV) vector product development, process development, and manufacturing.